Prologue Medicines creates transformative medicines by systematically discovering and evaluating viral proteins and their unique features.
Prologue Medicines has raised $50.0M in total funding. The most recent round was Series A. The last funding was announced in May 2024.
Prologue Medicines's investors include Flagship Pioneering.
Prologue Medicines is headquartered in Cambridge, United States.
Prologue Medicines creates transformative medicines by systematically discovering and evaluating viral proteins and their unique features.
Prologue Medicines is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Prologue Medicines — Funding & Investors." VCBacked, May 7, 2024, https://www.vcbacked.co/company/prologue-medicines. Accessed October 6, 2026.
VCBacked. (2024). Prologue Medicines — Funding & Investors. Retrieved October 6, 2026, from https://www.vcbacked.co/company/prologue-medicines
{{cite web |title=Prologue Medicines — Funding & Investors |url=https://www.vcbacked.co/company/prologue-medicines |website=VCBacked |access-date=October 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated